Insider · CIK 0001794629
Martin Javier San
officer
Files at LONA (Athira Pharma, Inc.). First filing Jan 3, 2025, latest Jul 2, 2025.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 2
$0 bought, $9,265 sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 20Weak | Athira Pharma, Inc. | $3,182 10,842 shares | -13% | - | |
| 20Weak | Athira Pharma, Inc. | $6,083 10,826 shares | -23% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Dec 24, 2025 | LONA Athira Pharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +44,508 | $0.00 | $0 | 44,508 | Dec 29, 2025 |
| Jun 30, 2025 | LONA Athira Pharma, Inc. | MOption exercise Common Stock | +46,666 | $0.00 | $0 | 82,507 | Jul 2, 2025 |
| Jul 1, 2025 | LONA Athira Pharma, Inc. | SOpen-market sale Common Stock | -10,842 | $0.29 | $3,182 | 71,665 | Jul 2, 2025 |
| Jun 30, 2025 | LONA Athira Pharma, Inc. | MOption exercise Restricted Stock Unitsderivative | -46,666 | $0.00 | $0 | 46,667 | Jul 2, 2025 |
| Mar 3, 2025 | LONA Athira Pharma, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +111,270 | $0.00 | $0 | 111,270 | Mar 4, 2025 |
| Mar 3, 2025 | LONA Athira Pharma, Inc. | AGrant or award Restricted Stock Unitsderivative | +74,180 | $0.00 | $0 | 74,180 | Mar 4, 2025 |
| Dec 31, 2024 | LONA Athira Pharma, Inc. | MOption exercise Common Stock | +46,667 | $0.00 | $0 | 46,667 | Jan 3, 2025 |
| Jan 2, 2025 | LONA Athira Pharma, Inc. | SOpen-market sale Common Stock | -10,826 | $0.56 | $6,083 | 35,841 | Jan 3, 2025 |
| Dec 31, 2024 | LONA Athira Pharma, Inc. | MOption exercise Restricted Stock Unitsderivative | -46,667 | $0.00 | $0 | 93,333 | Jan 3, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.